Even AbbVie CEO can't confirm Rinvoq's sales as FDA mulls JAK label

[cafead]

via When the FDA dropped the bombshell that it would add more safety warnings and restrict the use of JAK inhibitors, industry watchers began weighing the impact on a key player: AbbVie’s Rinvoq. But right now, even AbbVie’s CEO isn’t sure how much damage the update will do.

article source